Featured
Drugs slated to exit Australia in 2027
Two well-known cancer drugs that historically generated around $50 million in annual sales each will be removed from the Australian market in the first half of 2027
Regulatory & Reimbursement
Why this therapy must move to an earlier line
Half of the cancer patients who received a one-shot therapy remain progression free after five years, follow-up results show
Pipeline & Intellectual Property
Archrivals face battle with a new enemy
This newcomer is set to disrupt a longtime rivalry between two Big Pharmas in a highly competitive space after stunning phase 3 results
Jobs & Workplace
Talent on the move: who's up, who's new, who's left
With only one quarter remaining of 2026, companies are already lining up their talent for next year with a flurry of promotions and new hires
Industry & Companies
Trial failure throws future of pharma into doubt
ASX-listed biopharma has gone into voluntary administration, seeking to preserve its intellectual property after a catastrophic Phase 3 trial failure
Pipeline & Intellectual Property
CSL makes $1.7B bet on first-in-class hopeful
Exclusive global partnership to co-develop and co-promote a potential game-changing therapy across a range of kidney and liver diseases
Regulatory & Reimbursement
Aussie first hits lucrative market
Roche is delivering the first innovative solution of its kind to Australian patients with the company already heading to the PBAC for reimbursement
Featured
Jobs go as pharma restructure hits Australia
While the exact number of roles or business functions impacted has not been officially disclosed, it’s understood redundancies have hit the commercial team
Featured
Novartis General Manager departs
Well-known GM for New Zealand says he's looking forward to spending time with family, recharging, and exploring what's next
Regulatory & Reimbursement
Fourth sponsor enters hot biosimilar market
A new competitor to what was once the top-selling drug on the PBS plus approval for the first generic of a drug first registered in Australia in 1991
Regulatory & Reimbursement
First rival but no price cut for $20M drug
Even though three 'first new brands' hit onto the PBS at the start of October in competition with this $20M drug, there's been no price cut
Industry & Companies
Number of Best Workplaces in Aussie Pharma doubles
Now in its third year, the industry-specific list, compiled by Great Places to Work has doubled in size, with 10 companies making the cut in 2026
Jobs
Regulatory & Reimbursement
Longer US life... but what about Australia?
An Australian-developed drug forecast to earn half a billion this year just got another five years of patent protection in the US but plans for Australian registration are still missing
Pipeline & Intellectual Property
Has Lilly moved the goal posts in weight loss?
Impressive new trial results may have changed what weight loss drugs need to achieve to grab a slice of the market
Regulatory & Reimbursement
October listing a win for complex condition
A treatment that provides a much-needed alternative option for people with atopic dermatitis has hit the PBS
Featured
First rival triggers price cut for $70M drug
Biosimilar maker picks up three reimbursements for October, one of which triggered a statutory 25 per cent price cut for a $70M-a-year drug
Regulation & Legal
Info sheet breaches Aussie Code
Materials informing HCPs of a change to PBS criteria were worded in a way that breached the Code of Conduct, an MA Committee has determined
Regulatory & Reimbursement
Drug approvals slide in Australia
After a mammoth year of prescription drug approvals in 2025, the registration of both new drugs and new indications for existing medicines fizzles
Regulatory & Reimbursement
Govt trumpets groundbreaking cancer results
An 86 per cent complete response rate from a study that combined three drugs sponsored by AbbVie, BMS, and Roche has been shared by a State Government as part of its election commitment
Pipeline & Intellectual Property
AZ buys in before Summit's peak?
In what could be a savvy move, AZ has acquired more than 10 per cent of Summit Therapeutics ahead of much-hyped trial results
Industry & Companies
Who's Australia's Most Trusted (and Distrusted) pharma?
When it comes to trust and distrust two pharmas stand out, Australian research has found. See who's on a winning streak
Industry & Companies
Patients pick ANZ's best pharma
The pharma with industry's best Corporate Reputation jumped five places to take the top spot, thanks to an overwhelming response from patients who had worked with the company
Industry & Companies
Biogen staff spread early Christmas cheer
The volunteering experience provided employees with a first-hand understanding of the scale of community need and the importance of supporting vulnerable Australians
Industry & Companies
Women in pharma hit milestone
Ahead of its much-anticipated end-of-year event next month, this fledgling Australian branch of a global networking group has already passed a major milestone
Jobs & Workplace
Tax reform could force Aussie jobs overseas
Peak body for life sciences professionals warns a raft of Aussie pharma roles could move overseas if certain changes to the R&D Tax Incentive go through
Regulatory & Reimbursement
Time to use the C-word for multiple myeloma?
After analysing trial results which produced astounding results J&J is optimistic for a future where MM is no longer defined as incurable
- Industry & Companies Trump nabs secret slice of Aussie drug prices
- Sales, Marketing & Public Relations Lilly hit by health industry backlash
- Regulation & Legal TGA goes to court over prescription meds
- Sales, Marketing & Public Relations New tool puts KOLs on pharma's radar
- Sales, Marketing & Public Relations TV star speaks out for GSK campaign
- Regulatory & Reimbursement PBAC unpacks pet peeves about pharma
- Regulatory & Reimbursement First new drug in almost 20 years launched
- Industry & Companies Missing data sinks Aussie Phase 3 trial
- Regulatory & Reimbursement Hyped drug approved after 5-plus years
- Regulatory & Reimbursement Takeda snaps up recently vacated market
